Details for Patent: 9,949,997
✉ Email this page to a colleague
Which drugs does patent 9,949,997 protect, and when does it expire?
Patent 9,949,997 protects SYNJARDY XR, JARDIANCE, and SYNJARDY, and is included in three NDAs.
Protection for SYNJARDY XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-one patent family members in twenty-three countries.
Summary for Patent: 9,949,997
| Title: | Pharmaceutical composition, methods for treating and uses thereof |
| Abstract: | The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes. |
| Inventor(s): | Broedl; Uli Christian (Mainz am Rhein, DE), Johansen; Odd-Erik (Hoevik, NO), Kim; Gabriel Woojai (Mainz am Rhein, DE), Mayoux; Eric Williams (Schemmerhofen, DE), Salsali; Afshin (Princeton, NJ), Soleymanlou; Nima (Maple, CA), von Eynatten; Maximilian (Mainz, DE), Woerle; Hans-Juergen (Munich, DE), Cherney; David Z. I. (Toronto, CA), Perkins; Bruce A. (Toronto, CA), Daiber; Andreas (Scheessel, DE), Muenzel; Thomas (Mainz, DE) |
| Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
| Application Number: | 14/918,713 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,949,997 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,949,997
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-001 | Dec 9, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-002 | Dec 9, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-003 | Dec 9, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-004 | Dec 9, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Boehringer Ingelheim | JARDIANCE | empagliflozin | TABLET;ORAL | 204629-001 | Aug 1, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,949,997
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014247091 | ⤷ Try a Trial | |||
| Australia | 2019202568 | ⤷ Try a Trial | |||
| Canada | 2812016 | ⤷ Try a Trial | |||
| Canada | 2908621 | ⤷ Try a Trial | |||
| Chile | 2015002941 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
